Kadimastem Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KMSTF research report →
Price Chart
About the company
Kadimastem Ltd, an Israeli biopharmaceutical company, focuses on pioneering regenerative medicine therapies that utilize cells originating from human embryonic stem cells, primarily targeting neurodegenerative disorders. Its developmental pipeline features AstroRx, a clinical-grade human astrocyte therapy presently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Additionally, the company is developing IsletRx, a clinical-grade pancreatic islet cell therapy designed to treat diabetes.
- CEO
- Ronen Twito
- IPO
- 2021
- Employees
- 11
- HQ
- Ness Ziona, IL
Get TickerSpark's AI analysis on KMSTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.50M
- P/E
- -4.41
- PEG
- 0.04
- P/S
- 0.00
- P/B
- -4.02
- EV/EBITDA
- -24.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 158.49%
- ROIC
- 680.93%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,525,537-142.1%
- Op Income
- $-6,590,042
- Net Income
- $-26,491,872-119.9%
- EPS
- $-6.33-59.4%
- OCF Growth
- +75.2%
- FCF Growth
- +75.0%
- 52W High
- $9.07
- 52W Low
- $0.64
- 50D MA
- $6.79
- 200D MA
- $7.25
- Beta
- 0.57
- RSI (14)
- 36
- Avg Volume
- 40.24K
No earnings-call transcripts are available for KMSTF yet.
- Free Float
- 20.2%
- Shares Outstanding
- 2.96M
- Float Shares
- 598.14K
Our KMSTF coverage
Recent articles, reports, and earnings notes.
No research on KMSTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KMSTF report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.